首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Normal Tissue Complication Probability after hypofractionation increased due to the high dose per fraction or the high total Biological Equivalent Dose?
【24h】

Normal Tissue Complication Probability after hypofractionation increased due to the high dose per fraction or the high total Biological Equivalent Dose?

机译:正常组织并发症低分馏后的机率是由于每部分的剂量高或总生物等效剂量高?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Two recently published studies analysed the toxicity after hyp-ofractionated radiotherapy (RT) [1,2]. An important question is: could this toxicity be predicted from the delivered dose and historical toxicity models or was it unexpectedly high?The total biological dose for an Organ-At-Risk (OAR) after conventional fractionated radiotherapy (RT) is calculated as the Biological Equivalent Dose (BED) or Normalized Total Dose in 2 Gy per fraction {NTD_(2Gy)) according to the Linear Quadratic (LQ) model [3]. For hypofractionated regimens however, it is questionable whether the LQ-model is still valid [4,5]. Nowadays, more clinical data with longer follow-up are becoming available. It is important that the dose response analyses are accurately performed in order to answer the question whether the LQ model is valid and whether established dose-response relationships for OARs after conventional RT can be used after hypofractionated RT.
机译:最近发表的两项研究分析了超分割放疗(RT)后的毒性[1,2]。一个重要的问题是:是否可以通过所提供的剂量和历史毒性模型来预测这种毒性?还是它出乎意料的高?常规分次放疗(RT)后器官风险(OAR)的总生物剂量被计算为生物剂量根据线性二次(LQ)模型,等效剂量(BED)或归一化总剂量为每级分2 Gy(NTD_(2Gy))[3]。然而,对于超分割方案,LQ模型是否仍然有效[4,5]。如今,越来越多的具有更长随访时间的临床数据变得可用。重要的是,必须准确执行剂量反应分析,以回答LQ模型是否有效以及常规RT后OAR的已建立剂量反应关系是否可用于次分次RT后使用的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号